載入中
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
前收盤價
US$25.54
−US$0.13 · -0.51%
盤中時間採用ET。市場資料可能有所延遲。
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
日內區間
目前US$25.54
52週區間
目前US$25.54
盤中時間採用ET。市場資料可能有所延遲。
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
日內區間
目前US$25.54
52週區間
目前US$25.54
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB1227.74萬0.12%108.2億 USD0.44%US$206.49+3.00%
American Century Focused Dynamic Growth ETFFDG331.63萬0.81%4.35億 USD0.45%US$138.7+1.57%
ALPS Medical Breakthroughs ETFSBIO231.37萬1.21%1.91億 USD0.50%US$55.04+2.03%
Fidelity Fundamental Small-Mid Cap ETFFFSM224.05萬0.14%14.4億 USD0.43%US$34.13+0.62%
State Street SPDR Portfolio Emerging Markets ETFSPEM214.72萬0.01%175.23億 USD0.07%US$52.21+1.32%
Roundhill Investments - GLP-1 & Weight Loss ETFOZEM116.23萬2.10%5528.53萬 USD0.59%US$29.6009+1.06%
American Century Mid Cap Growth Impact ETFMID96.02萬0.95%1.46億 USD0.45%US$72.81+1.30%
TrueShares Technology, AI and Deep Learning ETFLRNZ85.81萬1.91%4488.05萬 USD0.68%US$69.015+2.09%iShares Biotechnology ETFIBBAmerican Century Focused Dynamic Growth ETFFDGALPS Medical Breakthroughs ETFSBIOFidelity Fundamental Small-Mid Cap ETFFFSMState Street SPDR Portfolio Emerging Markets ETFSPEMRoundhill Investments - GLP-1 & Weight Loss ETFOZEMAmerican Century Mid Cap Growth Impact ETFMIDTrueShares Technology, AI and Deep Learning ETFLRNZAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
